Effect of transfused donor and autoerythrocytes on the oncological outcomes of surgical treatment in patients with renal cell carcinoma with tumor-related venous thrombosis: observational study
- 作者: Volkova M.1,2, Feoktistov P.3, Begaliev A.2, Shin A.3, Matveev V.3, Prikhodchenko A.4
-
隶属关系:
- Russian Medical Academy of Continuous Professional Education
- City Clinical Oncology Hospital №1
- Blokhin National Medical Research Center of Oncology
- Scientific and Educational Center “Eurasian Cancer Program EAFO”
- 期: 卷 25, 编号 1 (2023)
- 页面: 133-139
- 栏目: CLINICAL ONCOLOGY
- URL: https://journals.rcsi.science/1815-1434/article/view/132807
- DOI: https://doi.org/10.26442/18151434.2023.1.202103
- ID: 132807
如何引用文章
全文:
详细
Background. The only effective treatment for renal cell carcinoma with tumor inferior vena cava (IVC) thrombosis is surgery. Nephrectomy with thrombectomy (NETE) is usually associated with clinically significant blood loss. The role of blood-sparing methods using autoerythrocyte reinfusion device (ARD) or replacement of blood loss with donor erythrocytes (DE) on the outcomes of NETE has not been well studied.
Aim. To study the rate of hemostasis disorders with intraoperative ARD use, as well as the effect of ARD and DE transfusions on specific (SS), relapse-free (RFS), and progression-free (PFS) survival of patients with renal cell carcinoma (RCC) after NETE.
Materials and methods. The observational study included medical data of 507 patients with RCC and tumor IVC thrombosis operated after NETE. The median volume of blood loss was 4000 [2000–6500] mL. In 312 (61.5%) patients, ARD without a leukocyte filter was used to compensate for blood loss (median volume of reinfused autoerythrocytes – AE was 1140 [700; 1900] mL). Transfusion of DE was required in 387 (76.3%) cases; the median number of DE transfused doses was 3 [1; 5]; 475 (93.7%) patients were discharged from the hospital. The median follow-up of all surviving patients was 24 (1–189) months.
Results. Indications for blood transfusions (DE and AE) were directly correlated to the pN (r=0.101; p=0.024) and pT (r=0.091; p=0.040) categories, respectively. The use of AE had no significant effect on the rate of hemostasis disorders and coagulopathic complications compared to other methods of blood loss replacement: 6.8% (21/311) vs 4.7% (9/193), p=0.227; 5.1% (16/311) vs 4.1% (8/193), p=0.394, respectively. ARD had no effect on SS, RFS (after radical surgery), and PFS (after cytoreductive surgery) after NETE. There was a reduction of SS in patients who received DE transfusions compared with those who did not (hazard ratio 0.4; 95% confidence interval 0.1–0.9; p=0.048). The effects of DE transfusions on RFS and PFS were not identified.
Conclusion. Intraoperative ARD use is an effective and safe method of correcting anemia, which does not increase the risk of coagulopathic complications or decrease survival rates. The non-use of the leukocyte filter during AE preparation does not worsen the medium-term oncological results of RCC surgical treatment with tumor IVC thrombosis. The effect of DE transfusion on the survival of RCC patients after NETE requires further research.
作者简介
Maria Volkova
Russian Medical Academy of Continuous Professional Education; City Clinical Oncology Hospital №1
编辑信件的主要联系方式.
Email: mivolkova6@gmail.com
ORCID iD: 0000-0001-7754-6624
D. Sci. (Med.), Russian Medical Academy of Continuous Professional Education, City Clinical Oncology Hospital №1
俄罗斯联邦, Moscow; MoscowPavel Feoktistov
Blokhin National Medical Research Center of Oncology
Email: mivolkova6@gmail.com
ORCID iD: 0000-0001-6024-5817
Cand. Sci. (Med.), Blokhin National Medical Research Center of Oncology
俄罗斯联邦, MoscowAdilet Begaliev
City Clinical Oncology Hospital №1
Email: mivolkova6@gmail.com
ORCID iD: 0000-0002-0755-7421
Cand. Sci. (Med.), City Clinical Oncology Hospital №1
俄罗斯联邦, MoscowAlexandr Shin
Blokhin National Medical Research Center of Oncology
Email: mivolkova6@gmail.com
ORCID iD: 0000-0002-3595-3472
Cand. Sci. (Med.), Blokhin National Medical Research Center of Oncology
俄罗斯联邦, MoscowVsevolod Matveev
Blokhin National Medical Research Center of Oncology
Email: mivolkova6@gmail.com
ORCID iD: 0000-0001-7748-9527
D. Sci. (Med.), Prof., Corr. Memb. RAS, Blokhin National Medical Research Center of Oncology
俄罗斯联邦, MoscowAleksey Prikhodchenko
Scientific and Educational Center “Eurasian Cancer Program EAFO”
Email: mivolkova6@gmail.com
ORCID iD: 0000-0002-4770-0034
Cand. Sci. (Med.), Scientific and Educational Center “Eurasian Cancer Program EAFO”
俄罗斯联邦, Moscow参考
- Волкова М.И., Вашакмадзе Н.Л., Климов А.В., и др. Прогноз оперированных больных раком почки с опухолевым венозным тромбозом: опыт клиники урологии НМИЦ онкологии им. Н.Н. Блохина. Онкоурология. 2021;17(3):19-28 [Volkova MI, Vashakmadze NL, Klimov AV, et al. Prognosis of patients operated on for renal cell carcinoma and tumor venous thrombosis: experience of the Urology Clinics, N.N. Blokhin National Medical Research Center of Oncology. Cancer Urology. 2021;17(3):19-28 (in Russian)].
- Parra J, Drouin SJ, Hupertan V, et al. Oncological outcomes in patients undergoing radical nephrectomy and vena cava thrombectomy for renal cell carcinoma with venous extension: a single-centre experience. Eur J Surg Oncol. 2011;37(5):422-8.
- Helfand BT, Smith ND, Kozlowski JM, Eskandari MK. Vena cava thrombectomy and primary repair after radical nephrectomy for renal cell carcinoma: Single-center experience. Ann Vasc Surg. 2011;25(1):39-43.
- Delis S, Dervenis C, Lytras D, et al. Liver transplantation techniques with preservation of the natural venovenous bypass: effect on surgical resection of renal cell carcinoma invading the inferior vena cava. World J Surg. 2004;28(6):614-9.
- Vamvakas EC. Perioperative blood transfusion and cancer recurrence: meta-analysis for explanation. Transfusion. 1995;35(9):760-8.
- Amato AC, Pescatori M. Effect of perioperative blood transfusions on recurrence of colorectal cancer: meta-analysis stratified on risk factors. Dis Colon Rectum. 1998;41(5):570-85.
- Soubra A, Zabell JR, Adejoro O, Konety BR. Effect of perioperative blood transfusion on mortality for major urologic malignancies. Clin Genitourin Cancer. 2015;13(3):e173-81.
- Linder BJ, Thompson RH, Leibovich BC, et al. The impact of perioperative blood transfusion on survival after nephrectomy for non-metastatic renal cell carcinoma (RCC). BJU Int. 2014;114(3):368-74.
- Atzil S, Arad M, Glasner A, et al. Blood transfusion promotes cancer progression: a critical role for aged erythrocytes. Anesthesiology. 2008;109(6):989-97.
- Upile T, Jerjes W, Mahil J, et al. Blood product transfusion and cancer prognosis. Clin Adv Hematol Oncol. 2009;7(10):656-61.
- Kozek-Langenecker SA, Ahmed AB, Afshari A, et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology: First update 2016. Eur J Anaesthesiol. 2017;34(6):332-95. doi: 10.1097/EJA.0000000000000630
- Tran DH, Wong GT, Chee YE, Irwin MG. Effectiveness and safety of erythropoiesis-stimulating agent use in the perioperative period. Expert Opin Biol Ther. 2014;14(1):51-61.
- Popovsky MA, Devine PA, Taswell HF. Intraoperative autologous transfusion. Mayo Clin Proc. 1985;60(2):125-34.
- Buth J, Raines JK, Kolodny GM, Darling RC. Effect of intraoperative autotransfusion on red cell mass and red cell survival. Surg Forum. 1975;26:276-8.
- Ray JM, Flynn JC, Bierman AH. Erythrocyte survival following intraoperative autotransfusion in spinal surgery: an in vivo comparative study and 5-year update. Spine (Phila Pa 1976). 1986;11(9):879-82.
- Homann B, Zenner HP, Schauber J, Ackermann R. Tumor cells carried through autotransfusion. Are these cells still malignant? Acta Anaesthesiol Belg. 1984;35(Suppl.):51-9.
- Miller GV, Ramsden CW, Primrose JN. Autologous transfusion: an alternative to transfusion with banked blood during surgery for cancer. Br J Surg. 1991;78(6):713-5.
- Klezl P, Pospisilova E, Kolostova K, et al. Detection of Circulating Tumor Cells in Renal Cell Carcinoma: Disease Stage Correlation and Molecular Characterization. J Clin Med. 2020;9(5):1372.
- Oefelein MG, Kaul K, Herz B, et al. Molecular detection of prostate epithelial cells from the surgical field and peripheral circulation during radical prostatectomy. J Urol. 1996;155(1):238-42.
- Weiss L. Metastatic inefficiency: causes and consequences. Cancer Rev. 1986;3:1-24.
- Frietsch T, Steinbicker AU, Horn A, et al. Safety of Intraoperative Cell Salvage in Cancer Surgery: An Updated Meta-Analysis of the Current Literature. Transfus Med Hemother. 2022;49(3):143-57.
- Moskowitz DM, Perelman SI, Cousineau KM, et al. Multidisciplinary management of a Jehovah’s Witness patient for the removal of a renal cell carcinoma extending into the right atrium. Can J Anaesth. 2002;49(4):402-8.
- Casey RG, Raheem OA, Elmusharaf E, et al. Renal cell carcinoma with IVC and atrial thrombus: a single centre’s 10 year surgical experience. Surgeon. 2013;11(6):295-9.
- Klimberg I, Sirois R, Wajsman Z, Baker J. Intraoperative autotransfusion in urologic oncology. Arch Surg. 1986;121(11):1326-9.
- Lyon TD, Ferroni MC, Turner RM, et al. Shortterm outcomes of intraoperative cell saver transfusion during open partial nephrectomy. Urology. 2015;86(6):1153-8.
- Zhang X, Guo X, Zong Y. CTCs detection from intraoperative salvaged blood in RCC–IVC thrombus patients by negative enrichment and iFISH identification: a preliminary study. BMC Urol. 2021;21(1):89.
- Carless PA, Henry DA, Moxey AJ, et al. Cell salvage for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev. 2010;3:CD001888.
- Domen RE. Adverse reactions associated with autologous blood transfusion: evaluation and incidence at a large academic hospital. Transfusion. 1998;38(3):296-300.